Currently a clinic trial of engineered TCR-T cells targeting one to five neoantigens (NCT05349890) is going on with PD-1 inhibitors and CD4 agonists (Table 3). Although most TCR-T studies are still in the preclinical stage, it shows great potential to cancer patients with tumor-specific mutations. The gene discussed is CD4; the disease is neoplasm.